Develops antiviral drugs for influenza and COVID-19.
Dec 2025Revenue $2.79M/yrExpenses $20.7M/yr
No trend
Figures by year
When will Traws Pharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $2.79M and expenses $20.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.79M | $20.7M | −$17.9M |
| Dec 2024 | $226K | $143M | −$142M |
| Dec 2023 | $226K | $20.5M | −$20.3M |
| Dec 2022 | $226K | $19.9M | −$19.6M |
| Dec 2021 | $226K | $16.7M | −$16.5M |
| Dec 2020 | $231K | $25.2M | −$25.0M |
| Dec 2019 | $2.18M | $23.9M | −$21.7M |
| Dec 2018 | $1.23M | $24.5M | −$23.3M |
| Dec 2017 | $787K | $26.5M | −$25.7M |
| Dec 2016 | $5.55M | $29.2M | −$23.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.